Valuation: Cytosorbents Corporation

Market Cap 2.4Cr 2.1Cr 1.94Cr 1.81Cr 3.41Cr 226.61Cr 3.48Cr 23Cr 9Cr 111.8Cr 9Cr 8.8Cr 388.14Cr P/E 2026 *
-2.06x
P/E 2027 * 12.7x
Enterprise Value 2.4Cr 2.1Cr 1.94Cr 1.81Cr 3.41Cr 226.61Cr 3.48Cr 23Cr 9Cr 111.8Cr 9Cr 8.8Cr 388.14Cr EV / Sales 2026 *
0.63x
EV / Sales 2027 * 0.51x
Free-Float
84.28%
Yield 2026 *
-
Yield 2027 * -
1 day+5.44%
1 week-7.58%
Current month-22.24%
1 month-22.24%
3 months-35.63%
6 months-42.18%
Current year-40.28%
1 week 0.35
Extreme 0.3504
0.52
1 month 0.35
Extreme 0.3504
0.6
Current year 0.35
Extreme 0.3504
0.84
1 year 0.35
Extreme 0.3504
1.3
3 years 0.35
Extreme 0.3504
4.29
5 years 0.35
Extreme 0.3504
9.8
10 years 0.35
Extreme 0.3504
14.95
Manager TitleAgeSince
Chief Executive Officer 55 24/07/2008
President 68 28/04/2020
Director of Finance/CFO 62 14/08/2024
Director TitleAgeSince
Chairman 62 -
Director/Board Member 55 01/01/2009
Director/Board Member 77 25/07/2011
Date Insider Type Main position Quantity % Market Cap.
15/06Buy

Chief Executive Officer

10,333 0.0165%
15/06Buy

Chief Financial Officer

1,00,000 0.1592%
18/11Free

Chief Executive Officer

1,00,000 0.1593%
Change 5-day change 1-year change 3-year change Capi.($)
+5.44%-7.58%-68.97%-89.37% 2.4Cr
-1.29%+9.14%+24.04%-1.55% 19TCr
+0.31%+0.75%-23.93%+19.94% 14TCr
-1.74%+8.19%-3.03%-18.92% 14TCr
-1.70%-1.92%-59.19%-18.41% 6.46TCr
+0.44%+6.17%+16.58%-0.91% 5.25TCr
+1.07%-0.49%-27.01%-33.76% 4.34TCr
-2.34%+5.01%+11.46%+12.52% 3.75TCr
-1.48%+2.96%+4.67%+40.82% 3.62TCr
-1.08%+7.27%-12.54%-17.32% 2.96TCr
Average +0.97%+3.27%-13.79%-10.70% 7.32TCr
Weighted average by Cap. +0.42%+5.68%-4.41%-1.74%

Financials

2026 *2027 *
Net sales 3.83Cr 3.35Cr 3.09Cr 2.89Cr 5.44Cr 361.76Cr 5.56Cr 37Cr 14Cr 178.47Cr 14Cr 14Cr 619.62Cr 4.71Cr 4.13Cr 3.81Cr 3.56Cr 6.7Cr 445.52Cr 6.85Cr 46Cr 18Cr 219.79Cr 18Cr 17Cr 763.09Cr
Net income -1.17Cr -1.03Cr -94.91L -88.62L -1.67Cr -111Cr -1.71Cr -11Cr -4.41Cr -55Cr -4.41Cr -4.31Cr -190.13Cr 23.73L 20.78L 19.18L 17.91L 33.72L 22Cr 34.49L 2.31Cr 89.11L 11Cr 89.12L 87.16L 38Cr
Net Debt - -
Logo Cytosorbents Corporation
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.
Employees
129
Date Price Change Volume
29/26/29 $0.3817 +5.44% 1,50,089
26/26/26 $0.3620 -21.30% 3,29,631
25/26/25 $0.4600 -1.50% 54,718
24/26/24 $0.4670 +8.86% 5,80,854
23/26/23 $0.4290 +3.87% 50,517
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.3817USD
Average target price
2.875USD
Spread / Average Target
+653.21%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CTSO Stock